Efficacy of esketamine in the treatment of negative symptoms in schizophrenia - A case series

Schizophr Res. 2018 Dec:202:394-396. doi: 10.1016/j.schres.2018.06.034. Epub 2018 Jun 21.

Authors

Marcel V Nunes¹, Marcelo P M Adelino¹, Elias Ajub¹, Lucas C Quarantini², Acioly L T Lacerda³

Affiliations

¹ Center for Research and Clinical Trials Sinapse-Bairral, Instituto Bairral de Psiquiatria, Itapira, Brazil.
² Department of Neurosciences and Mental Health, Universidade Federal da Bahia, Salvador, Brazil.
³ Center for Research and Clinical Trials Sinapse-Bairral, Instituto Bairral de Psiquiatria, Itapira, Brazil; Department of Psychiatry, Universidade Federal de São Paulo, São Paulo, Brazil. Electronic address: acioly@institutosinapse.org.

PMID: 29935883
DOI: 10.1016/j.schres.2018.06.034

No abstract available

Keywords: Glutamate; Ketamine; NMDA receptor; Negative symptoms; Psychosis; Treatment.

Publication types

Case Reports
Letter

MeSH terms

Adult
Excitatory Amino Acid Antagonists / administration & dosage
Excitatory Amino Acid Antagonists / pharmacology*
Female
Humans
Ketamine / administration & dosage
Ketamine / pharmacology*
Male
Middle Aged
Receptors, N-Methyl-D-Aspartate / antagonists & inhibitors*
Schizophrenia / drug therapy*
Schizophrenia / physiopathology*
Treatment Outcome
Young Adult

Substances

Excitatory Amino Acid Antagonists
Receptors, N-Methyl-D-Aspartate
Esketamine
Ketamine